CVS Health Upgraded to 'Outperform' by Sanford C. Bernstein

Analysts see potential 24% upside for the pharmacy operator's stock.

Mar. 12, 2026 at 1:10pm

Got story updates? Submit your updates here. ›

CVS Health (NYSE:CVS) was upgraded by stock analysts at Sanford C. Bernstein from a 'market perform' rating to an 'outperform' rating. Bernstein set a $94 price target on the stock, indicating a potential upside of 24.12% from the company's previous close.

Why it matters

The upgrade from a respected brokerage firm suggests analysts see strong growth potential for CVS Health as the company continues to expand its integrated healthcare model combining retail pharmacies, walk-in clinics, and insurance offerings.

The details

Sanford C. Bernstein cited CVS Health's diversified business model and growth opportunities as reasons for the upgrade. Other analysts have also recently increased their price targets for CVS, with Piper Sandler raising its target to $101 and Morgan Stanley increasing its target to $93.

  • The upgrade was issued on Thursday, March 12, 2026.

The players

Sanford C. Bernstein

A respected stock brokerage and research firm.

CVS Health

A diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services, and health care solutions.

Got photos? Submit your photos here. ›

What’s next

Investors will be watching to see if CVS Health can deliver on the growth potential highlighted by the Sanford C. Bernstein upgrade, as the company continues to expand its integrated healthcare model.

The takeaway

The Sanford C. Bernstein upgrade underscores the market's confidence in CVS Health's diversified business strategy and growth prospects, as the company looks to capitalize on trends towards integrated healthcare solutions.